St. Gallen Konsensus 2011 trifft AGO-Mammaempfehlung: Ein vergleichender Überblick

Zusammenfassung

In der 12. St. Gallener meinungsbildenden Konsensuskonferenz zur adjuvanten Therapie des Mammakarzinoms, stimmte ein internationales Expertenpanel zu über 100 Fragen zum kompletten Therapiespektrum zur adjuvanten Mammakarzinomtherapie ab. Der differenzierte Vergleich der Abstimmung des St. Gallener Panels (SGP) im Vergleich zu den aktuellen deutschen Empfehlungen verdeutlicht, dass die jeweils sehr individuellen und lokalen Sichtweisen der Panel-Mitglieder, die aus deutscher Sicht bezüglich der Anwendbarkeit und vor dem Hintergrund des deutschen Gesundheitssystems nicht eins zu eins übertragbar sind. 

Abstract

The 12^th St. Gallen consensus panel opinionized on more than 100 questions covering the entire adjuvant therapeutic spectrum of breast cancer. The differentiated comparison of the St. Gallen Panel (SGP) results versus the German recommendations and guidelines highlights individual and local opinions, which in terms of applicability and in view of the German health system cannot be easily adapted. 

Schlüsselwörter

adjuvante Therapie - Empfehlungen - operative Therapie - Bestrahlung - Chemotherapie

Key words

adjuvant therapy - guidelines - excision therapy - radiation - chemotherapy

Literatur

• 1 Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 1. Aktualisierung 2008 ISBN: 978-3-88603-934-0
• 2 Empfehlungen der Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie. deutsche Version 11.1.0 2011 http://http://www.ago-online.de/index.php?lang=de&site=mamma_guide_topical& topic=mamma_guide
• 3 Seeking consensus on evidence and opinions about optimal treatment of early breast cancer. Saturday, 19 March 2011. Chair: Aron Goldhirsch, Switzerland and William Wood, USA, Secretary: Giuseppe Curigliano, Italy, Participants of the St. Gallen 2011 international breast cancer consensus panel: Matti Aapro (Switzerland), Kathy Albain (USA), José Baselga (USA), Jonas Bergh (Sweden), Hervè Bonnefoi (France), Harold Burstein (USA), Monica Castiglione-Gertsch (Switzerland), Alan Coates (Australia), Marco Colleoni (Italy), Alberto Costa (Italy), Nancy Davidson (USA), Angelo Di Leo (Italy), Bent Ejlertsen (Denmark), John F. Forbes (Australia), Richard D. Gelber (USA), Agnes Glaus (Switzerland), John H. Glick (USA), Michael Gnant (Austria), Pamela Goodwin (Canada), Paul E. Goss (USA), Jay R. Harris (USA), Dan Hayes (USA), James Ingle (USA), Jacek Jassem (Poland), Zefei Jiang (China), Per Karlsson (Sweden), Manfred Kaufmann (Germany), Gunter von Minckwitz (Germany), Monica Morrow (USA), Moise Namer (France), Larry Norton (USA), C. Kent Osborne (USA), Frédérique Penault-Llorca (France), Charles Perou (USA), Martine Piccart-Gebhart (Belgium), Kurt Possinger (Germany), Kathy Pritchard (Canada), Emiel J.T. Rutgers (The Netherlands), Vladimir Semiglazov (Russia), Ian Smith (UK), Beat Thürlimann (Switzerland), Masakazu Toi (Japan), Andrew Tutt (UK), Michael Untch (Germany), Giuseppe Viale (Italy), Toru Watanabe (Japan), Nicholas Wilcken (Australia), Eric Winer (USA).
• 4 Cote R, Giuliano A E, Hawes D et al. ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1 / T2 N0 M0 breast cancer.  J Clin Oncol. 2010;  28 8
• 5 Giuliano A E, Hunt K K, Ballman K V et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.  JAMA. 2011;  305 569-575
• 6 Giuliano A E, McCall L, Beitsch P et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.  Ann Surg. 2010;  252 426-432 discussion 432–433
• 7 Wittekind C et al. TNM-Klassifikation maligner Tumoren.. 7. Aufl. Weinheim: Wiley-VCH Verlag; 2010
• 8 Cheang M C, Chia S K, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.  J Natl Cancer Inst. 2009;  101 736-750
• 9 Harbeck N, Salem M, Nitz U et al. Personalized treatment of early-stage breast cancer: present concepts and future directions.  Cancer Treat Rev. 2010;  36 584-594
• 10 Sverrisdottir A, Johansson H, Johansson U et al. Interaction between Goserelin and Tamoxifen in acontrolled clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.  SABCS. 2010;  Abstract S1–S5
• 11 Mouridsen H. The BIG 1–98 Collaborative Group . Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer.  N Engl J Med. 2009;  361 766-776
• 12 NCCN-Guidelines. http://http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
• 13 Joensuu H, Kellokumpu-Lehtinen P L, Huovinen R et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide epirubicin for breast cancer: an open-label, randomised controlled trial.  Lancet Oncol. 2009;  10 1145-1151
• 14 von Minckwitz G. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. 12th International St. Gallen Breast Cancer Conference 16–19 March 2011 / St. Gallen, Switzerland (SG-BCC 2011).
• 15 von Minckwitz G, Kaufmann M, Kümmel S et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane + / – trastuzumab containing chemotherapy. SABCS; 2008
• 16 Liedtke C, Mazouni C, Hess K R ABCSG-12 Trial Investigators et al. Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer.  NEJM. 2009;  360 679-691
• 17 Yerushalmi R, Hayes M M, Gelmon K A et al. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.  Clin Breast Cancer. 2009;  9 166-172
• 18 Chang H R, Glaspy J, Allison M A et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.  Cancer. 2010;  116 4227-4237
• 19 Chen X S, Nie X Q, Chen C M et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.  Ann Oncol. 2010;  21 961-967
• 20 Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.  J Clin Oncol. 2010;  28 375-379
• 21 Gianni L, Pienkowski T, Im Y H et al. Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study (‘NeoSphere’).  Cancer Res. 2010;  70 82
• 22 Baselga J, Bradbury I, Eidtmann H NeoALTTO Study Team et al., on Behalf of the. First Results of the NeoALTTO Trial (BIG 01–06 / EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer.  Cancer Res. 2010;  70 82
• 23 Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.  Ann Oncol. 2010;  21 2188-2194
• 24 Coleman R, Thorpe H, Cameron D et al. Adjuvant treatment with zoledronic acid in stage II / III breast cancer. SABCS; 2010 The AZURE Trial (BIG01 / 04). Abstr. 533.